Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption

Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption

Abstract INTRODUCTION: Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance. METHODS: Data were obtained from ICUs between 2010 and 2013. RESULTS: P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B. CONCLUSIONS: Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.

Saved in:
Bibliographic Details
Main Authors: Ribeiro,Ághata Cardoso da Silva, Crozatti,Márcia Terezinha Lonardoni, Silva,Adilson Aderito da, Macedo,Rodrigo Spineli, Machado,Antonia Maria de Oliveira, Silva,Antonio Távora de Albuquerque
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Medicina Tropical - SBMT 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000100602
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract INTRODUCTION: Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance. METHODS: Data were obtained from ICUs between 2010 and 2013. RESULTS: P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B. CONCLUSIONS: Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.

Similar Items